Targeting the tumor microenvironment: focus on angiogenesis.

PubWeight™: 1.09‹?› | Rank: Top 10%

🔗 View Article (PMC 3163131)

Published in J Oncol on August 24, 2011

Authors

Fengjuan Fan1, Alexander Schimming, Dirk Jaeger, Klaus Podar

Author Affiliations

1: Medical Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

Articles citing this

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07

Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int (2014) 0.98

Recruitment and retention: factors that affect pericyte migration. Cell Mol Life Sci (2013) 0.90

Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci (2014) 0.89

Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin (2013) 0.89

The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene (2015) 0.87

LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J Biol Chem (2013) 0.84

Postoperative simple biochemical markers for prediction of bone metastases in Egyptian breast cancer patients. Ecancermedicalscience (2013) 0.81

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma. Curr Signal Transduct Ther (2014) 0.81

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. Oncoimmunology (2013) 0.80

A novel 99mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: a pilot study. PLoS One (2013) 0.80

Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? Oncotarget (2017) 0.80

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. J Immunother Cancer (2015) 0.77

E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis. BMC Cancer (2015) 0.77

Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma. Oral Oncol (2012) 0.77

Lunasin Attenuates Obesity-Associated Metastasis of 4T1 Breast Cancer Cell through Anti-Inflammatory Property. Int J Mol Sci (2016) 0.77

Cross-talk between endothelial and tumor cells via basic fibroblast growth factor and vascular endothelial growth factor signaling promotes lung cancer growth and angiogenesis. Oncol Lett (2015) 0.76

Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Ann Lab Med (2015) 0.76

The immunological effect of hyaluronan in tumor angiogenesis. Clin Transl Immunology (2015) 0.75

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget (2016) 0.75

FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget (2016) 0.75

Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue. NPJ Syst Biol Appl (2016) 0.75

Articles cited by this

(truncated to the top 100)

Hallmarks of cancer: the next generation. Cell (2011) 140.01

The hallmarks of cancer. Cell (2000) 113.05

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88

A genetic model for colorectal tumorigenesis. Cell (1990) 44.37

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25

Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01

Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58

Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08

Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43

Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03

Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73

Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95

mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86

Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46

Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27

Renal-cell carcinoma. N Engl J Med (2005) 10.17

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92

Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21

Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16

Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (1989) 8.10

VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95

VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86

TRANSPLANTABILITY OF TISSUES TO THE EMBRYO OF FOREIGN SPECIES : ITS BEARING ON QUESTIONS OF TISSUE SPECIFICITY AND TUMOR IMMUNITY. J Exp Med (1913) 7.70

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 7.46

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun (1989) 7.39

Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29

Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18

Renal cell carcinoma. Lancet (2009) 6.92

Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48

The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol (2011) 6.30

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23

Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21

Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54

Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev (1996) 5.17

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 5.07

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer (2002) 5.02

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01

Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 4.98

Rules for making human tumor cells. N Engl J Med (2002) 4.84

Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62

Multiple myeloma. Lancet (2009) 4.60

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37

Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 4.18

Modelling breast cancer: one size does not fit all. Nat Rev Cancer (2007) 3.64

The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer (2004) 3.58

The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) (2005) 3.24

Vasculogenic mimicry and tumor angiogenesis. Am J Pathol (2000) 3.19

Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer (2006) 3.19

Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A (2000) 3.16

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12

The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature (2004) 2.95

Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol (1997) 2.82

Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science (2006) 2.78

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.69

Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res (1999) 2.55

Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50

Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol (2000) 2.50

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45

NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40

Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A (2001) 2.36

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (2008) 2.36

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol (2009) 2.34

Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest (2010) 2.32

Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol (2009) 2.31

Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res (2004) 2.27

Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol (2010) 2.22

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol (2009) 2.18

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res (1994) 2.13

VHL and HIF signalling in renal cell carcinogenesis. J Pathol (2010) 2.13

Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res (2001) 2.12

Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst (1998) 2.09

Articles by these authors

Multiple myeloma. Lancet (2009) 4.60

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65

Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39

Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res (2011) 2.08

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood (2007) 1.89

Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg (2007) 1.85

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res (2005) 1.84

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood (2004) 1.82

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res (2006) 1.75

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell (2009) 1.73

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol (2010) 1.73

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res (2003) 1.70

Mcl-1 regulation and its role in multiple myeloma. Cell Cycle (2004) 1.68

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res (2003) 1.66

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol (2004) 1.64

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res (2006) 1.62

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood (2007) 1.60

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood (2006) 1.56

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood (2008) 1.55

Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother (2013) 1.53

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther (2002) 1.50

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opin Pharmacother (2012) 1.47

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood (2004) 1.46

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene (2002) 1.45

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol (2006) 1.45

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res (2005) 1.42

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res (2004) 1.42

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood (2009) 1.41

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol (2007) 1.41

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene (2004) 1.38

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene (2003) 1.34

Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem (2006) 1.31

JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem (2003) 1.26

Cytokines and signal transduction. Best Pract Res Clin Haematol (2005) 1.25

Dephosphorylation of Ser-259 regulates Raf-1 membrane association. J Biol Chem (2001) 1.25

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res (2005) 1.25

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood (2007) 1.24

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood (2005) 1.23

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood (2007) 1.21

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res (2009) 1.16

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res (2003) 1.16

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res (2005) 1.15

Real-time definition of non-randomness in the distribution of genomic events. PLoS One (2007) 1.14

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood (2009) 1.13

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood (2003) 1.12

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology (2006) 1.09

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res (2005) 1.09

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res (2004) 1.05

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res (2002) 1.04

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood (2002) 1.03

Retracted CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood (2009) 1.01

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood (2004) 1.01

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood (2002) 1.01

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res (2008) 1.01

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther (2009) 1.00

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood (2009) 1.00

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood (2003) 0.99

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood (2002) 0.99

Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. Int J Cancer (2008) 0.98

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene (2005) 0.97

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood (2008) 0.97

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene (2004) 0.97

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res (2012) 0.95

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood (2005) 0.95

Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. Anticancer Res (2009) 0.94

Estimation of immune cell densities in immune cell conglomerates: an approach for high-throughput quantification. PLoS One (2009) 0.94

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res (2004) 0.93

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol (2006) 0.91

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene (2005) 0.91

Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem (2010) 0.90

Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene (2003) 0.90

Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther (2013) 0.90

Automatic tumor-stroma separation in fluorescence TMAs enables the quantitative high-throughput analysis of multiple cancer biomarkers. PLoS One (2011) 0.89

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. Exp Hematol (2002) 0.89

Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. Oncology (2008) 0.86

Neoadjuvant treatment does not influence perioperative outcome in rectal cancer surgery. Int J Radiat Oncol Biol Phys (2009) 0.86

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood (2004) 0.85

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood (2002) 0.85

Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology (2012) 0.84

Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Oncoimmunology (2013) 0.82

Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother (2006) 0.82

Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol (2010) 0.82

New insights, recent advances, and current challenges in the biological treatment of multiple myeloma. Expert Opin Biol Ther (2013) 0.81

Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice. Anticancer Res (2013) 0.79

beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol (2002) 0.78

The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way ahead. Oncoimmunology (2012) 0.78

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 0.77

Protein S100 as prognostic marker for gastrointestinal stromal tumors: a clinicopathological risk factor analysis. J Invest Surg (2007) 0.77

Posterior reversible leukoencephalopathy syndrome associated with pazopanib. Case Rep Oncol (2013) 0.75

Exercise and cancer: return to work as a firefighter with ostomy after rectal carcinoma - a case report. Medicine (Baltimore) (2016) 0.75

Efficacy and safety of trastuzumab-based therapy in combination with different chemotherapeutic regimens in advanced esophagogastric cancer--a single cancer-center experience. Tumori (2014) 0.75